OR10G3

Across TCGA pan-cancer cohorts, OR10G3 Mutation is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated OR10G3 data layer compared with 6 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher OR10G3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR10G3 expression acts as an unfavorable survival marker.

SCLC, OV, and HNSC are the cancer types where OR10G3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	III,IV	0.082	0.548	.003	24	view →
OV	DFS	Median	All	0.064	0.541	<.001	18	view →
HNSC	DFS	Median	All	0.209	0.710	.032	12	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	8	view →
CHOL	DFS	Median	All	0.037	0.486	.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	DFS	Median	All	0.198	0.587	.025	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR10G3–SCLC (DFS)

Open the SCLC breakdown →